Sabril (SAY-bril, vigabatrin) is a new oral therapy for refractory epilepsy and infantile spasms

Sabril (SAY-bril, vigabatrin) is a new oral therapy for refractory epilepsy and infantile spasms.

Use of this drug will be restricted because it can cause permanent vision loss in about 30% of patients.

This vision loss is a progressive narrowing of the visual field. The risk increases with higher doses or longer duration.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

  • 12 issues every year, with brief articles about new meds and guidelines
  • 48+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote